nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GABRB3—GABA A receptor activation—GABRA3—Graves' disease	0.0363	0.0745	CbGpPWpGaD
Acamprosate—GABRG2—GABA A receptor activation—GABRA3—Graves' disease	0.0357	0.0732	CbGpPWpGaD
Acamprosate—GABRA1—GABA A receptor activation—GABRA3—Graves' disease	0.0312	0.064	CbGpPWpGaD
Acamprosate—Lymphadenopathy—Methimazole—Graves' disease	0.0286	0.0557	CcSEcCtD
Acamprosate—Lymphadenopathy—Propylthiouracil—Graves' disease	0.0243	0.0474	CcSEcCtD
Acamprosate—Renal failure acute—Propylthiouracil—Graves' disease	0.0225	0.0438	CcSEcCtD
Acamprosate—GABRB3—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0222	0.0456	CbGpPWpGaD
Acamprosate—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.022	0.0428	CcSEcCtD
Acamprosate—GABRG2—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0218	0.0448	CbGpPWpGaD
Acamprosate—GABRA1—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0191	0.0392	CbGpPWpGaD
Acamprosate—Hepatitis—Methimazole—Graves' disease	0.0169	0.0329	CcSEcCtD
Acamprosate—Alopecia—Methimazole—Graves' disease	0.0149	0.0291	CcSEcCtD
Acamprosate—Haemoglobin—Propylthiouracil—Graves' disease	0.0144	0.0281	CcSEcCtD
Acamprosate—Haemorrhage—Propylthiouracil—Graves' disease	0.0143	0.028	CcSEcCtD
Acamprosate—Hepatitis—Propylthiouracil—Graves' disease	0.0143	0.028	CcSEcCtD
Acamprosate—Vertigo—Methimazole—Graves' disease	0.0132	0.0257	CcSEcCtD
Acamprosate—Leukopenia—Methimazole—Graves' disease	0.0131	0.0256	CcSEcCtD
Acamprosate—Alopecia—Propylthiouracil—Graves' disease	0.0127	0.0247	CcSEcCtD
Acamprosate—Myalgia—Methimazole—Graves' disease	0.0125	0.0244	CcSEcCtD
Acamprosate—Arthralgia—Methimazole—Graves' disease	0.0125	0.0244	CcSEcCtD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.0123	0.0253	CbGpPWpGaD
Acamprosate—Dysgeusia—Propylthiouracil—Graves' disease	0.0122	0.0238	CcSEcCtD
Acamprosate—GABRB3—GABA receptor activation—GABRA3—Graves' disease	0.0118	0.0242	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Methimazole—Graves' disease	0.0117	0.0229	CcSEcCtD
Acamprosate—GABRG2—GABA receptor activation—GABRA3—Graves' disease	0.0116	0.0238	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.0115	0.0236	CbGpPWpGaD
Acamprosate—Vertigo—Propylthiouracil—Graves' disease	0.0112	0.0219	CcSEcCtD
Acamprosate—Leukopenia—Propylthiouracil—Graves' disease	0.0112	0.0218	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Methimazole—Graves' disease	0.0109	0.0213	CcSEcCtD
Acamprosate—Paraesthesia—Methimazole—Graves' disease	0.0108	0.021	CcSEcCtD
Acamprosate—Somnolence—Methimazole—Graves' disease	0.0107	0.0208	CcSEcCtD
Acamprosate—Myalgia—Propylthiouracil—Graves' disease	0.0106	0.0207	CcSEcCtD
Acamprosate—Arthralgia—Propylthiouracil—Graves' disease	0.0106	0.0207	CcSEcCtD
Acamprosate—Dyspepsia—Methimazole—Graves' disease	0.0105	0.0206	CcSEcCtD
Acamprosate—GABRA1—GABA receptor activation—GABRA3—Graves' disease	0.0101	0.0208	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00997	0.0194	CcSEcCtD
Acamprosate—Urticaria—Methimazole—Graves' disease	0.00952	0.0186	CcSEcCtD
Acamprosate—Body temperature increased—Methimazole—Graves' disease	0.00947	0.0185	CcSEcCtD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00942	0.0193	CbGpPWpGaD
Acamprosate—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00928	0.0181	CcSEcCtD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00928	0.0191	CbGpPWpGaD
Acamprosate—Paraesthesia—Propylthiouracil—Graves' disease	0.00915	0.0178	CcSEcCtD
Acamprosate—Somnolence—Propylthiouracil—Graves' disease	0.00906	0.0177	CcSEcCtD
Acamprosate—Dyspepsia—Propylthiouracil—Graves' disease	0.00897	0.0175	CcSEcCtD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00863	0.0177	CbGpPWpGaD
Acamprosate—Pruritus—Methimazole—Graves' disease	0.00848	0.0165	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00822	0.0169	CbGpPWpGaD
Acamprosate—Urticaria—Propylthiouracil—Graves' disease	0.00809	0.0158	CcSEcCtD
Acamprosate—Body temperature increased—Propylthiouracil—Graves' disease	0.00805	0.0157	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00801	0.0165	CbGpPWpGaD
Acamprosate—Vomiting—Methimazole—Graves' disease	0.00762	0.0149	CcSEcCtD
Acamprosate—Rash—Methimazole—Graves' disease	0.00755	0.0147	CcSEcCtD
Acamprosate—Dermatitis—Methimazole—Graves' disease	0.00755	0.0147	CcSEcCtD
Acamprosate—Headache—Methimazole—Graves' disease	0.00751	0.0146	CcSEcCtD
Acamprosate—Pruritus—Propylthiouracil—Graves' disease	0.00721	0.0141	CcSEcCtD
Acamprosate—Nausea—Methimazole—Graves' disease	0.00712	0.0139	CcSEcCtD
Acamprosate—GRIN2C—Neuronal System—GABRA3—Graves' disease	0.00711	0.0146	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00708	0.0145	CbGpPWpGaD
Acamprosate—GABRB3—Orphan transporters—GABRA3—Graves' disease	0.00688	0.0141	CbGpPWpGaD
Acamprosate—GABRG2—Orphan transporters—GABRA3—Graves' disease	0.00675	0.0139	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—GABRA3—Graves' disease	0.00661	0.0136	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—FAS—Graves' disease	0.00655	0.0134	CbGpPWpGaD
Acamprosate—Vomiting—Propylthiouracil—Graves' disease	0.00648	0.0126	CcSEcCtD
Acamprosate—Rash—Propylthiouracil—Graves' disease	0.00642	0.0125	CcSEcCtD
Acamprosate—Dermatitis—Propylthiouracil—Graves' disease	0.00642	0.0125	CcSEcCtD
Acamprosate—Headache—Propylthiouracil—Graves' disease	0.00638	0.0124	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00618	0.0127	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—FAS—Graves' disease	0.00609	0.0125	CbGpPWpGaD
Acamprosate—Nausea—Propylthiouracil—Graves' disease	0.00605	0.0118	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00602	0.0124	CbGpPWpGaD
Acamprosate—GABRA1—Orphan transporters—GABRA3—Graves' disease	0.0059	0.0121	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—GABRA3—Graves' disease	0.00543	0.0111	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00542	0.0111	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00533	0.0109	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—TSHR—Graves' disease	0.00522	0.0107	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—FAS—Graves' disease	0.005	0.0103	CbGpPWpGaD
Acamprosate—GABRB3—Ion channel transport—GABRA3—Graves' disease	0.00483	0.00991	CbGpPWpGaD
Acamprosate—GABRG2—Ion channel transport—GABRA3—Graves' disease	0.00474	0.00973	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—GABRA3—Graves' disease	0.00473	0.00972	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00465	0.00956	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—GABRA3—Graves' disease	0.00462	0.00948	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00453	0.0093	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—FAS—Graves' disease	0.00436	0.00895	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—FAS—Graves' disease	0.00425	0.00873	CbGpPWpGaD
Acamprosate—GABRA1—Ion channel transport—GABRA3—Graves' disease	0.00414	0.0085	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CXCL10—Graves' disease	0.00411	0.00845	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00408	0.00837	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.004	0.00822	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—IL1B—Graves' disease	0.00383	0.00786	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—IL1B—Graves' disease	0.00356	0.00731	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0035	0.00718	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CXCL10—Graves' disease	0.00337	0.00692	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—GABRA3—Graves' disease	0.00312	0.00641	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—GABRA3—Graves' disease	0.00307	0.0063	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—TSHR—Graves' disease	0.00295	0.00605	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—IL1B—Graves' disease	0.00292	0.006	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—TNF—Graves' disease	0.00278	0.00571	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—ICAM1—Graves' disease	0.00273	0.0056	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—GABRA3—Graves' disease	0.00268	0.0055	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—TSHR—Graves' disease	0.00268	0.00549	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—TNF—Graves' disease	0.00258	0.00531	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—IL1B—Graves' disease	0.00255	0.00524	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—IL1B—Graves' disease	0.00249	0.00511	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—TNF—Graves' disease	0.00212	0.00436	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IFNG—Graves' disease	0.00207	0.00426	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—CXCL10—Graves' disease	0.0019	0.00391	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TNF—Graves' disease	0.00185	0.0038	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IL1B—Graves' disease	0.00185	0.0038	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TNF—Graves' disease	0.0018	0.0037	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—CXCL10—Graves' disease	0.00173	0.00355	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00168	0.00345	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00165	0.00339	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TSHR—Graves' disease	0.00158	0.00325	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.00148	0.00304	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—IL2RA—Graves' disease	0.00146	0.00299	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00144	0.00296	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TNF—Graves' disease	0.00134	0.00276	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL2RA—Graves' disease	0.00132	0.00271	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—TNF—Graves' disease	0.00107	0.0022	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CXCL10—Graves' disease	0.00102	0.0021	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000838	0.00172	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL2RA—Graves' disease	0.000781	0.0016	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000608	0.00125	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TNF—Graves' disease	0.000427	0.000877	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—TNF—Graves' disease	0.000416	0.000855	CbGpPWpGaD
